Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $16.00 at Chardan Capital

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price trimmed by Chardan Capital from $17.00 to $16.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright decreased their price target on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Citizens Jmp upgraded shares of Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Wednesday. The Goldman Sachs Group restated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Finally, Barclays raised their price target on shares of Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Iovance Biotherapeutics Stock Up 1.3%

Shares of NASDAQ IOVA opened at $3.83 on Wednesday. The stock has a market capitalization of $1.52 billion, a PE ratio of -3.42 and a beta of 0.76. The firm has a fifty day moving average of $2.67 and a 200-day moving average of $2.41. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.64.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative return on equity of 54.09% and a negative net margin of 148.41%.The business had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Equities research analysts expect that Iovance Biotherapeutics will post -1.24 EPS for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. bought a new position in Iovance Biotherapeutics in the third quarter worth about $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Iovance Biotherapeutics in the 3rd quarter worth about $27,000. Arcataur Capital Management LLC bought a new stake in Iovance Biotherapeutics in the 4th quarter valued at about $29,000. Granite Investment Partners LLC acquired a new position in Iovance Biotherapeutics during the 4th quarter valued at about $29,000. Finally, Motley Fool Asset Management LLC bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $29,000. Institutional investors own 77.03% of the company’s stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q4 results beat expectations (narrower loss, $86.8M revenue) with Amtagvi sales up ~33% and management pointing to improved margins and pipeline momentum. This is a primary earnings catalyst supporting the rally. IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
• Positive Sentiment: FDA approval and positive real‑world data for lifileucel (Amtagvi) have shifted the program from a pipeline bet toward commercial execution, increasing revenue visibility and investor enthusiasm. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Positive pilot sarcoma data (50% objective response rate in advanced soft‑tissue sarcomas) broadens Amtagvi’s potential label expansion and prompted immediate investor buying. This clinical readout is being treated as a material pipeline catalyst. Iovance Announces Positive Results for TIL Cell Therapy in Soft Tissue Sarcomas
• Positive Sentiment: Analyst sentiment is improving — Barclays raised its price target to $11 and Citizens JMP upgraded the stock — adding institutional validation to the move and supporting further upside potential. Analyst Coverage / Price Target Changes
• Positive Sentiment: Operational/volume story: coverage explaining a Philadelphia manufacturing/scale rationale helped investor confidence that commercial execution can improve, contributing to the weekly surge. Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
• Neutral Sentiment: Chardan trimmed its price target slightly (from $17 to $16) but kept a buy rating — a mixed signal (still bullish but slightly less aggressive). Chardan Lowers Price Target on Iovance
• Neutral Sentiment: Unusual options activity: a large one‑day increase in call buying was reported, signaling speculative bullish positioning but not confirming sustained fundamental buying. (Market flows can amplify moves.)
• Negative Sentiment: Short interest jumped ~24.8% in February to ~131.3M shares — ~36.9% of float — and a short‑interest ratio near 14.6 days. That raises potential for volatility (squeeze risk) but also indicates strong bearish positioning that could pressure the stock if fundamentals weaken.
• Negative Sentiment: Cash/runway and dilution risk remain material — analysts and sell‑side commentary flag that Iovance may need additional capital before Amtagvi generates steady cash flow, which could lead to future dilution. Seeking Alpha: Better Gross Margin And Faster Turnaround Support A Higher Floor

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.